PubRank

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

Clinical Trial ID NCT01134510

PubWeight™ 8.70‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01134510

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 5.39
2 Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008 4.32
3 The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012 1.71
4 Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004 1.68
5 Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013 1.64
6 Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 2010 0.90
7 An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. Am J Transplant 2015 0.89
8 The emerging role of complement inhibitors in transplantation. Kidney Int 2015 0.86
9 What's new in clinical solid organ transplantation by 2013. World J Transplant 2014 0.81
10 Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015 0.80
11 Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy. World J Transplant 2014 0.77
12 Reducing antibody levels in patients undergoing transplantation. N Engl J Med 2008 0.76
13 Complement cascade and kidney transplantation: The rediscovery of an ancient enemy. World J Transplant 2014 0.76
14 Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective. Clin Exp Immunol 2015 0.75
Next 100